Status:
COMPLETED
Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid
Lead Sponsor:
AstraZeneca
Conditions:
Alzheimer´s Disease
Eligibility:
All Genders
20-85 years
Phase:
PHASE1
Brief Summary
The study is carried out in order to investigate if \[11C\]AZD2995, compared to \[11C\]AZD2184, is a more suitable PET ligand for in vivo imaging of β amyloid depositions in the human brain. In the st...
Eligibility Criteria
Inclusion
- Alzheimer´s Disease patients - 50-85 years- mild to moderate AD, clinical progression of AD over 12 months.
- Healthy male volunteers: - Age 20-50 years, Body Mass Index: 18-30 kg/m2.
- Clinically normal physical findings including normal blood pressure and pulse rate.
Exclusion
- Alzheimer´s Disease patients:
- significant cerebrovascular disease or depression, central nervous system infarct or infection or lesions
- clinically significant illness within 2 weeks before the study start.
- administration of any investigational product with effect on brain beta amyloid levels within 3 months prior to study and/or participation in a PET investigation other than study D0180C00011 as part of a scientific study during the past 12 months,.
- Healthy volunteers; - clinically significant illness within 2 weeks before the study start, history of psychiatric or somatic disease/condition that may interfere.- first degree relative with dementia. Obvious deterioration of memory functions.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00692705
Start Date
January 1 2008
End Date
December 1 2008
Last Update
January 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Stockholm, Sweden